Vireo Growth (OTCMKTS:VREOD – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. 3.8% of Vireo Growth shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Vireo Growth and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 298.94%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Vireo Growth.
Risk and Volatility
Vireo Growth has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.
Valuation and Earnings
This table compares Vireo Growth and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
| Unicycive Therapeutics | $680,000.00 | 192.49 | -$26.56 million | ($1.75) | -2.69 |
Unicycive Therapeutics has lower revenue, but higher earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Unicycive Therapeutics beats Vireo Growth on 11 of the 14 factors compared between the two stocks.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.
